@GlennS, stop. Just stop. If you don't believe in the drug, get out. We are all tired of your s@*!
To be fair, I think it's good to have a variety of perspectives. I think there's something big that he's missing (I didn't understand this until recently as well).
There's a lot of speculation and theories after the Phase 2a failure. The stuff about inner hair cell prioritization and all of this other stuff is fair, but speculative. Why
exactly the trial failed is speculative.
The fact that inner and outer hair cells do completely different things is not. It really is true that someone can hear a word in a perfectly normal volume for them, but it sounds like gibberish. This didn't make any sense to me when I first thought about it. I thought maybe not hearing words was a combination of like straining and lack of clarity. When I really understood what was going on was when I watched Dr. Cliff's YouTube video about how for the WR test, the volume is set at a comfortable level for the listener to normalize for OHC loss.
Even if one takes the most pessimistic view possible, which is that the drug failed or it didn't and no bullshit about it, it's still definitely the case that WR and PTA are measured differently. The nuance to this, though, is that there is a
correlation between having both types of loss, even though they are different.
Hypothetically, we should be prepared (we are not there yet, I am not being too bullish too soon) for the first hearing regeneration drug to
possibly help one type first. I think PIPE-505 (synapse drug) purportedly may regenerate outer hair cells. Hence, if that drug makes it out of Phase 1, we may see some weird results as well.
To be clear, FX-322 doesn't have results yet. But this distinction is definitely not speculative.